The size of the In-Vitro Toxicology Testing Market in the Asia Pacific is expected to worth USD 8220.75 Million by 2027 from USD 3877.10 Million in 2022, growing at a CAGR of 16.22% during the forecast period.
In vitro tests provide information on toxicity cost-effectively and rapidly. Rapid advances in biomedical science should lead to newer and more advanced in vitro testing strategies for characterizing hazards.
Factors contributing to the growth of the In-vitro toxicology testing market in this region include encouraging advanced technologies, resistance to animal testing, inadequate databases to facilitate the use of In-vitro testing methods, and more R&D to determine early stage toxicity. The emergence of CROs for outsourcing research projects related to toxicology, opposition to animal testing leading to the use of alternative methods, the increase in the portfolio of pharmaceutical drugs, and the taking of growing consumers consciousness product safety are also supporting the market growth in APAC.
Additionally, ethical concerns and demand from animal activist groups concerning the use of animals for testing, banning of testing on animals on cosmetics, the support of regulatory bodies for approval In-vitro testing, the low costs associated with in vitro toxicology testing, and advances in vitro methodologies are also favoring the In-vitro toxicology testing market in the Asia Pacific.
Besides, the synergistic relationships between various industry players and the growth of toxicological databases to facilitate in vitro testing methods are expected to provide significant growth opportunities for players operating in this market. Driven by the strong demand for biopharmaceuticals, in vitro toxicology tests are the highest in the pharmaceutical industry. The heavy use of toxicology testing in the pharmacokinetic analysis of new and modified generic pharmaceuticals drives revenue growth from these toxicity testing assays. Besides, the presence of several pending drug candidates should stimulate demand for in vitro toxicology tests.
However, in vitro models' insufficiency to determine immune stimulation and autoimmunity and the predictive ability of in vitro tests compared to in vivo tests may hinder the growth of the market.
This market research report on the Asia Pacific in-vitro toxicology testing market has been segmented and sub-segmented into the following categories:
The Asia-Pacific region is expected to experience the fastest growth rate during the forecast period due to government agencies' increased initiatives to encourage acceptance of non-animal test models. Several governments are taking steps to minimize animal-based testing models, develop supportive government policies, and provide funds to support in vitro models. These factors are expected to create plenty of growth opportunities for the market. Additionally, conducting clinical trials in Asian countries such as China, Japan, and India is relatively cost-effective compared to Western countries. Several biopharmaceutical companies perform their drug development procedures in this region.
Key market competitors dominating the Asia Pacific in-vitro toxicology testing market profiled in this report are Covance, Inc. (A subsidiary of LabCorp), Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific SE, General Electric Company, BioReliance, Inc., Charles River Laboratories International, Inc., Thermo Fisher Scientific, Inc., Catalent and Cyprotex.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com